Position in LLY
as of Jun 30, 2026
· filed Aug 18, 2026
Position Value
$48,437,785
+$11,348,980 QoQ
Shares Held
40,384
+0.1% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
3.58%
of 13F equity value
Holder Rank
#557
of 4,605 holders
Holding Since
Jun 2021
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Kimelman & Baird, LLC holds $87,529,146 across 10 Drug Manufacturers - General names. LLY ranks #1 (55.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
40,384 | $48,437,785 | |
| 2 | MRK |
Merck & Co., Inc.
|
160,179 | $20,583,001 | |
| 3 | ABBV |
AbbVie Inc.
|
30,656 | $7,714,275 | |
| 4 | AMGN |
Amgen Inc
|
14,240 | $5,156,588 | |
| 5 | JNJ |
Johnson & Johnson
|
10,250 | $2,603,192 | |
| 6 | NVS |
Novartis AG
|
6,850 | $1,073,532 | |
| 7 | PFE |
Pfizer Inc
|
42,976 | $1,034,862 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
15,525 | $894,550 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $48,437,785 | 40,384 | Shares | Sole | 2026-08-18 | |
| 2026-03-31 | $37,088,805 | 40,324 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $45,005,453 | 41,878 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $33,357,597 | 43,719 | Shares | Sole | 2025-11-25 | |
| 2025-06-30 | $34,519,926 | 44,283 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $36,937,172 | 44,723 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $34,401,864 | 44,562 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $32,416,544 | 36,590 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $34,368,224 | 37,960 | Shares | Sole | 2024-08-19 | |
| 2021-06-30 | $14,689,280 | 64,000 | Shares | Sole | 2021-08-17 | |
| No filing history on record for this holder in this stock. | ||||||